Stubbe Beate, Halank Michael, Seyfarth Hans-Jürgen, Obst Anne, Desole Susanna, Opitz Christian F, Ewert Ralf
University Medicine Greifswald, Internal Medicine B, Pneumology, Greifswald.
Internal Medicine, Pneumology, University Hospital Dresden, Dresden, Germany.
Pneumologie. 2022 May;76(5):330-339. doi: 10.1055/a-1740-3377. Epub 2022 Apr 1.
Risk stratification plays an essential role in the management of patients with pulmonary arterial hypertension (PAH). According to the current European guidelines the expected 1-year risk of mortality for PAH patients can be categorized as low, intermediate, or high, based on clinical, non-invasive and hemodynamic data.Data from 131 patients with incident PAH (age 64 ± 14) and frequent comorbidities (in 66.4 %) treated between 2016 and 2018 at 4 German PH centers were analyzed. At baseline, most patients were classified as intermediate risk (76 %), 13.8 % as high risk and only 9.9 % as low risk.During follow-up while on treatment after 12 ± 3 months (range 9-16 months) 64.9 % were still classified as intermediate risk (76 %), 14.4 % as high risk and 20.7 % as low risk.Survival at 12 and 24 months was 96 % and 82 % in the intermediate risk group, while only 89 % and 51 % of the high risk patients were alive at these time points. In contrast, all patients in the low risk category were alive at 24 months.Despite the availability of various treatment options for patients with PAH even in specialized centers only a minority of patients can be stabilized in the low risk group associated with a good outcome.
风险分层在肺动脉高压(PAH)患者的管理中起着至关重要的作用。根据当前欧洲指南,基于临床、非侵入性和血流动力学数据,PAH患者的预期1年死亡风险可分为低、中、高三个类别。对2016年至2018年期间在德国4个肺动脉高压中心接受治疗的131例初发PAH患者(年龄64±14岁,66.4%伴有常见合并症)的数据进行了分析。基线时,大多数患者被归类为中度风险(76%),13.8%为高风险,仅9.9%为低风险。在随访期间,治疗12±3个月(范围9 - 16个月)后,64.9%的患者仍被归类为中度风险(76%),14.4%为高风险,20.7%为低风险。中度风险组12个月和24个月时的生存率分别为96%和82%,而高风险患者在这些时间点的生存率仅为89%和51%。相比之下,低风险组的所有患者在24个月时均存活。尽管PAH患者有多种治疗选择,即使在专科中心,也只有少数患者能够稳定在与良好预后相关的低风险组。